## Alessandro Martorana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1656143/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis. Journal of Neuroscience, 2009, 29, 3442-3452.	1.7	331
2	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. JAMA Neurology, 2014, 71, 1498.	4.5	262
3	Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. NeuroImage, 2018, 169, 302-311.	2.1	234
4	"Delirium Day― a nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. BMC Medicine, 2016, 14, 106.	2.3	204
5	ââ,¬Å"Is dopamine involved in Alzheimer's disease?ââ,¬Â• Frontiers in Aging Neuroscience, 2014, 6, 252.	1.7	202
6	Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?. CNS Neuroscience and Therapeutics, 2013, 19, 549-555.	1.9	159
7	Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients. Neuropsychopharmacology, 2009, 34, 2323-2328.	2.8	128
8	Impaired LTP- but not LTD-Like Cortical Plasticity in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 31, 593-599.	1.2	127
9	Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?. CNS Neuroscience and Therapeutics, 2010, 16, 235-245.	1.9	122
10	Dopaminergic Modulation of Cortical Plasticity in Alzheimer's Disease Patients. Neuropsychopharmacology, 2014, 39, 2654-2661.	2.8	121
11	Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiology of Disease, 2009, 36, 51-59.	2.1	108
12	Sub-cellular localization of manganese in the basal ganglia of normal and manganese-treated rats. NeuroToxicology, 2008, 29, 60-72.	1.4	103
13	Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiology of Aging, 2016, 40, 120-126.	1.5	96
14	Lowered cAMP and cGMP signalling in the brain during levodopaâ€induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. European Journal of Neuroscience, 2008, 28, 941-950.	1.2	95
15	Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology, 2017, 89, 665-672.	1.5	95
16	Dopamine D2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology, 2013, 64, 108-113.	2.0	84
17	Longâ€ŧerm potentiation–like cortical plasticity is disrupted in Alzheimer's disease patients independently from age of onset. Annals of Neurology, 2016, 80, 202-210.	2.8	79
18	Immunolocalization of CB1receptor in rat striatal neurons: A confocal microscopy study. Synapse, 2004, 53, 159-167.	0.6	75

#	Article	IF	CITATIONS
19	Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. European Journal of Neuroscience, 2004, 20, 989-1000.	1.2	72
20	Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. Proteomics, 2006, 6, 2305-2313.	1.3	70
21	Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2012, 165, 861-869.	2.7	67
22	Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. Annals of Neurology, 2020, 87, 394-404.	2.8	65
23	Transcranial magnetic stimulation predicts cognitive decline in patients withÂAlzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1237-1242.	0.9	64
24	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 525-532.	1.2	59
25	Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. European Journal of Neuroscience, 2003, 18, 1093-1102.	1.2	57
26	CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease. Scientific Reports, 2017, 7, 13728.	1.6	57
27	AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. Journal of the Neurological Sciences, 2005, 237, 83-88.	0.3	55
28	Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiology of Disease, 2007, 25, 266-273.	2.1	55
29	Tissue plasminogen activator is required for corticostriatal long-term potentiation. European Journal of Neuroscience, 2002, 16, 713-721.	1.2	52
30	CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the Neurological Sciences, 2006, 251, 124-128.	0.3	52
31	Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression. Journal of Alzheimer's Disease, 2016, 50, 605-616.	1.2	51
32	LTP-like cortical plasticity predicts conversion to dementia in patients with memory impairment. Brain Stimulation, 2020, 13, 1175-1182.	0.7	51
33	Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients. Frontiers in Aging Neuroscience, 2013, 5, 2.	1.7	48
34	Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. European Journal of Neuroscience, 2006, 23, 11-20.	1.2	46
35	LTP-like cortical plasticity is associated with verbal memory impairment in Alzheimer's disease patients. Brain Stimulation, 2019, 12, 148-151.	0.7	46
36	Activation of β1-Adrenoceptors Excites Striatal Cholinergic Interneurons through a cAMP-Dependent, Protein Kinase-Independent Pathway. Journal of Neuroscience, 2003, 23, 5272-5282.	1.7	45

#	Article	IF	CITATIONS
37	PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: A key step in parkinsonism physiopathology. Neurobiology of Disease, 2011, 43, 293-303.	2.1	45
38	Oligodendrocytes express P2Y12 metabotropic receptor in adult rat brain. Neuroscience, 2006, 141, 1171-1180.	1.1	44
39	Aβ1–42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Aβ1–42 aggregation?. Experimental Neurology, 2010, 223, 371-376.	2.0	44
40	l-dopa modulates motor cortex excitability in Alzheimer's disease patients. Journal of Neural Transmission, 2008, 115, 1313-1319.	1.4	43
41	Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clinical Neurophysiology, 2011, 122, 703-707.	0.7	43
42	Impaired Spike Timing Dependent Cortico-Cortical Plasticity in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2018, 66, 983-991.	1.2	43
43	Cerebrospinal Fluid A <i>β</i> <sub>42</sub> Levels: When Physiological Become Pathological State. CNS Neuroscience and Therapeutics, 2015, 21, 921-925.	1.9	41
44	Manganese intoxication decreases the expression of manganoproteins in the rat basal ganglia: An immunohistochemical study. Brain Research Bulletin, 2007, 74, 406-415.	1.4	40
45	Glaucoma progression associated with altered cerebral spinal fluid levels of amyloid beta and tau proteins. Clinical and Experimental Ophthalmology, 2011, 39, 279-281.	1.3	40
46	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. Frontiers in Neurology, 2015, 6, 86.	1.1	39
47	Association Between Alzheimer's Disease and Claucoma: A Study Based on Heidelberg Retinal Tomography and Frequency Doubling Technology Perimetry. Frontiers in Neuroscience, 2015, 9, 479.	1.4	39
48	CSF Tau Levels Influence Cortical Plasticity in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2011, 26, 181-186.	1.2	38
49	Frailty Among Alzheimer's Disease Patients. CNS and Neurological Disorders - Drug Targets, 2013, 12, 507-511.	0.8	36
50	Cellular localization of TRPC3 channel in rat brain: preferential distribution to oligodendrocytes. Neuroscience Letters, 2004, 365, 137-142.	1.0	34
51	Homotaurine Induces Measurable Changes of Short Latency Afferent Inhibition in a Group of Mild Cognitive Impairment Individuals. Frontiers in Aging Neuroscience, 2014, 6, 254.	1.7	34
52	Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnestic Presentation: CSF and 18F-FDG PET Study. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 108-119.	0.6	34
53	Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease. JAMA Network Open, 2020, 3, e2010372.	2.8	34
54	Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study. European Journal of Neuroscience, 2006, 24, 732-738.	1.2	31

#	Article	IF	CITATIONS
55	The Load of Amyloid-β Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 31, 865-878.	1.2	31
56	Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. Journal of Neural Transmission, 2012, 119, 771-778.	1.4	31
57	Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?. Neurochemistry International, 2014, 79, 44-56.	1.9	31
58	In vivo electrophysiology of dopamineâ€denervated striatum: Focus on the nitric oxide/cGMP signaling pathway. Synapse, 2008, 62, 409-420.	0.6	30
59	Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study. Brain Research, 2018, 1678, 116-122.	1.1	30
60	Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neuroscience Letters, 2008, 448, 166-169.	1.0	28
61	Intracellular localization and isoform expression of the voltage-dependent anion channel (VDAC) in normal and dystrophic skeletal muscle. Journal of Muscle Research and Cell Motility, 2000, 21, 433-442.	0.9	27
62	Adult polyglucosan body disease: Proton magnetic resonance spectroscopy of the brain and novel mutation in the <i>GBE1</i> gene. Muscle and Nerve, 2008, 37, 530-536.	1.0	27
63	Altered Parietal-Motor Connections in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 33, 525-533.	1.2	27
64	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. Journal of Neural Transmission, 2017, 124, 1621-1625.	1.4	27
65	Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. Journal of Alzheimer's Disease, 2020, 76, 681-689.	1.2	27
66	Effects of Cerebellar Theta Burst Stimulation on Contralateral Motor Cortex Excitability in Patients with Alzheimer's Disease. Brain Topography, 2020, 33, 613-617.	0.8	26
67	Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 76, 1297-1308.	1.2	26
68	D2-mediated modulation of N-type calcium currents in rat globus pallidus neurons following dopamine denervation. European Journal of Neuroscience, 2002, 15, 815-825.	1.2	25
69	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. Journal of Neurology, 2014, 261, 1832-1836.	1.8	25
70	Enkephalin, neurotensin, and substance P immunoreactivite neurones of the rat GP following 6-hydroxydopamine lesion of the substantia nigra. Experimental Neurology, 2003, 183, 311-319.	2.0	24
71	Transcranial magnetic stimulation: Emerging biomarkers and novel therapeutics in Alzheimer's disease. Neuroscience Letters, 2020, 719, 134355	1.0	23
72	Functional correlates of t-Tau, p-Tau and Aβ1–42 amyloid cerebrospinal fluid levels in Alzheimer's disease. Nuclear Medicine Communications, 2015, 36, 461-468.	0.5	22

#	Article	IF	CITATIONS
73	Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study. Scientific Reports, 2017, 7, 6220.	1.6	20
74	Plasmin system of Alzheimer's disease patients: CSF analysis. Journal of Neural Transmission, 2012, 119, 763-769.	1.4	18
75	Is cerebral glucose metabolism related to blood–brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?. Medicine (United States), 2016, 95, e4206.	0.4	18
76	P2Y1 receptor switches to neurons from glia in juvenile versus neonatal rat cerebellar cortex. BMC Developmental Biology, 2007, 7, 77.	2.1	17
77	Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer's Disease Patients. Current Alzheimer Research, 2018, 15, 628-636.	0.7	17
78	Huntingtin distribution among striatal output neurons of normal rat brain. Neuroscience Letters, 2003, 339, 53-56.	1.0	16
79	Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following reserpine treatment: Focus on kappa response. Synapse, 2004, 51, 194-205.	0.6	16
80	CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. Journal of Neural Transmission, 2012, 119, 861-875.	1.4	16
81	Assessment of serum uric acid as risk factor for tauopathies. Journal of Neural Transmission, 2017, 124, 1105-1108.	1.4	16
82	Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [18F] FDG a specific biomarker in these patients?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1796-1805.	3.3	14
83	Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. Neurobiology of Aging, 2021, 105, 333-339.	1.5	14
84	Apathy as Marker of Frail Status. Journal of Aging Research, 2012, 2012, 1-5.	0.4	13
85	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	0.9	11
86	Neurotensin effects on N-type calcium currents among rat pallidal neurons: An electrophysiological and immunohistochemical study. Synapse, 2006, 60, 371-383.	0.6	10
87	Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia. Minerva Medica, 2021, 112, 441-447.	0.3	10
88	Haemodynamic impairment along the Alzheimer's disease continuum. European Journal of Neurology, 2021, 28, 2168-2173.	1.7	7
89	Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype. European Journal of Neurology, 2021, 28, 3965-3971.	1.7	7
90	Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2. Minerva Medica, 2018, 109, 358-362.	0.3	7

#	Article	IF	CITATIONS
91	MANGANESE DETECTED BY ELECTRON SPECTROSCOPY IMAGING AND ELECTRON ENERGY LOSS SPECTROSCOPY IN MITOCHONDRIA OF NORMAL RAT BRAIN CELLS. Instrumentation Science and Technology, 2002, 20, 481-491.	0.8	6
92	The Brain Metabolic Correlates of the Main Indices of Neuropsychological Assessment in Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 25.	1.1	6
93	Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons. Synapse, 2001, 41, 360-362.	0.6	5
94	Kyphoplasty. American Journal of Physical Medicine and Rehabilitation, 2004, 83, 810-812.	0.7	5
95	Insulin and the Future Treatment of Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2016, 15, 660-664.	0.8	5
96	Transient global amnesia: Linked to a systemic disorder of amino acid catabolism?. Journal of Neurology, 2013, 260, 1429-1432.	1.8	4
97	Lacosamide in the Management of Behavioral Symptoms in Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2018, 32, 364-365.	0.6	4
98	The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease. Annals of Nuclear Medicine, 2020, 34, 254-262.	1.2	4
99	Ageing as a Trait de Union Between Diabetes and Dementia for Frailty. CNS and Neurological Disorders - Drug Targets, 2013, 12, 520-524.	0.8	4
100	Clinical Profile of Alzheimerâ $\in$ Ms Disease Non-Responder Patient. , 2011, , .		3
101	Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers. CNS and Neurological Disorders - Drug Targets, 2017, 16, 407-413.	0.8	2
102	Isolated Amyloid-β Pathology Is Associated with Preserved Cortical Plasticity in APOE4 Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2022, 86, 773-778.	1.2	2
103	Gammaâ€induction in frontotemporal dementia (GIFTeD) randomized placeboâ€controlled trial: Rationale, noninvasive brain stimulation protocol, and study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12219.	1.8	2
104	Editorial (Alzheimer's Disease and Frail Syndrome: Features Overlap Predictive of Poor Outcome). CNS and Neurological Disorders - Drug Targets, 2013, 12, 506-506.	0.8	0
105	D2 agonist administration restores altered cortical plasticity in Alzheimer's disease patients. Neurobiology of Aging, 2014, 35, S5-S6.	1.5	0
106	Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer's Dementia. Focus on Non) Tj ETQq0 15, 646-646.	0 0 rgBT / 0.8	Overlock 10 0
107	C57BL/6J and DBA/2J strains present opposite sex differences in flash visual evoked potential latency: A possible confusing factor in gender studies on neurological diseases' transgenic models. Brain Research Bulletin, 2021, 176, 18-24.	1.4	0

108 Manganese Toxicity: A Critical Reappraisal. , 2003, , 415-425.